Aldosterone to renin ratio (ARR) in clinical use, with reference to the primary care setting: ARR to whom, when, how, what for?

Current Hypertension Reviews

Volumn 4, Issue 4, 2008, Pages 227-233

  Olivieri, Oliviero ^a   Pizzolo, Francesca ^a   Corrocher, Roberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Aldosterone; Aldosteronism; ARR; Hypertension; Primary care; Renin

Indexed keywords

ALDOSTERONE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; RENIN; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; BREAST TENDERNESS; CLINICAL PRACTICE; DISEASE PREDISPOSITION; DRUG RESPONSE; ERECTILE DYSFUNCTION; FAMILY HISTORY; GYNECOMASTIA; HUMAN; HYPERTENSION; MASS SCREENING; MENSTRUATION DISORDER; PLASMA RENIN ACTIVITY; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEXUAL DYSFUNCTION;

EID: 70350002149     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340208786241327     Document Type: Review

References (69)

1. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Arch Intern Med 1981; 141: 1589-93.
2. Hamlet SM, Tunny TJ, Woodland E, Gordon RD. Is the aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism. Clin Exp Pharmacol Physiol 1985; 12: 249-52.
3. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism. J Clin Endocr Metab 1991; 73: 952-7.
4. Gordon RD, Ziezak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon - twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-8.
5. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-18.
6. Brown MA, Cramp HA, Zammit VC, Whitworth JA. Primary aldosteronism: a missed diagnosis in "essential hypertensives"? Aust NZ J Med 1996; 26: 533-538.
7. Young WF Jr. Primary aldosteronism: update on diagnosis and treatment, Endocrinologist 1997; 7: 213-21.
8. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40.
9. Kreze A Jr, Okalova D, Vanuga P, Putz Z, Kodaj J, Hrnciar J. Occurrence of primary aldosteronism in a group of ambulatory hypertensive patients. Vnitr Lek 1999; 45: 17-21.
10. Mosso L, Fardella C, Montero J, et al. High prevalence of undiagnosed primary hyperaldosteronism among patients with essential hypertension. Rev Med Child 1999; 127: 800-806.
11. Fardella CE, Mosso L, Gomez-Sanchez CE, et al. Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.
12. Loh K-C, Koay ES, Khaw M-C, Emmanuel SC, Young WF. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-9.
13. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-15.
14. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC, Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
15. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. South African Med J 2000; 90: 394-400.
16. Trenkel S, Seifart C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diab 2002; 110: 80-85.
17. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-300.
18. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-50.
19. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Primary aldosteronism: hypertension with a genetic basis. Lancet 1992; 340: 159-61.
20. Stowasser M, Gordon RD. Primary aldosteronism-careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217: 33-9.
21. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 6-17.
22. Kaplan NM. Primary aldosteronism. In Clinical Hypertension 9th ed. Philadelpha, PA: Lippincott, Williams and Wilkins 2006; 410-33.
23. Young WF. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 114: 2208-13.
24. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar BB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-6.
25. Kaplan NM. Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953-4.
26. Mulatero P, Dluhy RG, Giacchetti G, BoscaroM, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to sub-type differentiation. Trends Endocrinol Metab 2005; 16: 115-8.
27. Stowasser M, Gordon RD. Prevalence and diagnostic workup of primary aldosteronism: new knowledge and new approaches. Nephrology 2001; 6: 119-26.
28. Stowasser M. Primary aldosteronism: revival of a syndrome. J Hypertension 2000; 18: 363-6.
29. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertension 2000; 18: 1165-76.
30. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000; 85: 2160-66.
31. Mulatero P, Morra di Cella S, Williams TA, et al. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 2002; 87: 3187-91.
32. Olivieri O, Ciacciarelli A, Signorelli D, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89: 4221-6.
33. Fogari R, Preti P, Zoppi A, Rinaldi A, Fogari E, Mugellini A. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007; 30: 111-7.
34. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999; 48: 756-60.
35. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19: 353-61.
36. Mahmud A, Mahgoub M, Hall M, Feely J. Does Aldosterone-to-Renin Ratio Predict the Antihypertensive Effect of the Aldosterone Antagonist Spironolactone? Am J Hypertens 2005; 18:1631-5.
37. Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 8-10.
38. Newton-Cheh C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-56.
39. Aram V, Chobanian, Bakris GL, et al. the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52
40. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
41. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76: 877-82.
42. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002; 48: 1919-23.
43. Montori VM, Young WF Jr. Use of the plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-32.
44. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-94.
45. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489-94.
46. Gordon RD. The challenge of more robust and reproducible methodology in screening for primary aldosteronism. J Hypertens 2004; 22: 251-5.
47. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705.
48. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/ plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902.
49. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002; 57: 457-65.
50. Stowasser M, Gordon RD, Rutherford JC, Nikwan NZ, Daunt N, Slater GJ. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2: 156-69.
51. Young WF Jr. Primary aldosteronism: update in diagnosis and treatment. The Endocrinologist 1997; 7: 213-21.
52. Pizzolo F, Pavan C, Corrocher R, Olivieri O. Laboratory diagnosis of primary aldosteronism and drospirenone-ethinylestradiol therapy. Am J Hypertens 2007; 20: 1334-1337.
53. Schiffrin EL. Effects of Aldosterone on the Vasculature. Hypertension 2006; 47: 312-8.
54. Strauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimska J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19: 909-14.
55. Park S, Kim JB, Shim CY, et al. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007; 25: 1279-83.
56. Rossi GP, Sacchetto A, Visentin PA, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045.
57. Rossi GP, Di Bello V, Ganzaroli C, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-7.
58. Güder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115: 1754-61.
59. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
60. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
61. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 19:1243-8.
62. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-45.
63. Labinson PT, White WB, Tendler BE, Mansoor GA. Primary hyperaldosteronism associated with hypertensive emergencies. Am J Hypertens 2006; 19: 623-7.
64. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005;18: 50-5.
65. Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA. Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 2005; 46: 707-13.
66. Sartori M, Calà LA, Mascagna V, et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006;19: 373-9.
67. Chapman N, Dobson J, Wilson S, et al. on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:1-7.
68. National Institute for Health and Clinical Excellence. Clinical Guidelines Hypertension: management of hypertension in adults in primary care. http://www.nice.org.uk/CG034. 2006.
69. Williams B, Poulter NR, Brown MJ, et al. the BHS guidelines working party, for the British Hypertension Society8. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004; 328: 634-40.